Tempest Therapeutics, Inc. Common Stock
TPST
TPST: Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
moreShow TPST Financials
Recent trades of TPST by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by TPST's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Bicyclic compounds and their use in the treatment of cancer Aug. 29, 2023
-
Patent Title: Triazolone compounds and uses thereof Jun. 06, 2023
-
Patent Title: Bicyclic compounds and their use in the treatment of cancer May. 02, 2023
-
Patent Title: Bicyclic carboxamides and methods of use thereof Oct. 18, 2022
-
Patent Title: Bicyclic carboxamides and methods of use thereof Sep. 13, 2022
-
Patent Title: Bicyclic compounds and their use in the treatment of cancer Jul. 20, 2021
-
Patent Title: Bicyclic carboxamides and methods of use thereof Apr. 06, 2021
-
Patent Title: Triazolone compounds and uses thereof Feb. 25, 2020
-
Patent Title: Pyrazolone compounds and uses thereof Jan. 09, 2018
Federal grants, loans, and purchases
Followers on TPST's company Twitter account
Number of mentions of TPST in WallStreetBets Daily Discussion
Recent insights relating to TPST
Recent picks made for TPST stock on CNBC
ETFs with the largest estimated holdings in TPST
Flights by private jets registered to TPST